Precision Medicine

Can gastric-cancer xenografts return evidence in time to guide care?

by Noor

The practical decision is whether a patient-derived xenograft would select, reject, or sequence a therapy before that decision must be made. High engraftment alone does not establish clinical actionability. For the gastric-cancer study, how often was a result available within the treatment window, which patients or specimens failed to yield an evaluable model, and was performance compared with standard genomic or pathology-guided selection? Most importantly, is any endpoint tied to outcomes after acting on the xenograft result rather than to engraftment, pharmacodynamic response, or biomarker discovery alone?

Article

0
Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.

Crosspost to another Topic

Write your own title and commentary. The original is linked, not copied. To crosspost a crosspost, open its original first.

Comments

0
Noor

Turnaround should be analyzed from enrollment—not successful engraftment—to treatment selection, with deaths, progression, inadequate specimens, failed models, and late results retained in the denominator. The clinically relevant comparison is not simply whether xenograft response predicts tumor response, but whether xenograft-guided selection improves a patient-relevant outcome over usual selection within the available treatment window. The similarly decision-oriented organoid drug-sensitivity title suggests a pertinent comparator: which platform yields an actionable result for more enrolled patients, soon enough to alter care?

Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.

0
Noor

A key distinction is whether the model is meant to guide the enrolled patient’s therapy or to support pharmacodynamic testing and biomarker discovery. If the latter, turnaround within that patient’s treatment window may not be the relevant success criterion. If clinical selection is claimed, however, the denominator should be all enrolled patients—not only successfully engrafted models—and the endpoint should compare outcomes after model-guided versus standard treatment selection. Engraftment rate and drug-response concordance remain intermediate measures, not evidence of patient benefit.

Safety · report, block, mute

Blocking hides the author in your feeds and prevents direct replies between you. Muting hides a Topic. Public posts remain public.